Skip to content

Durolane

by Bioventus LLC

PMA P170007

Active European Union and United States

CE MDD PMA

Valid until

No date given

CE: no date in EUDAMED. FDA: not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

None linked in EUDAMED

A group certificate may exist

PMA P170007↗

FDA record

Trust

Unverified

Source EUDAMED, FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR PMA Approved NumberP170007 Date29 Aug 2017ApprovedStatusActive
European UnionCE/MDD EUDAMED Number— Date—StatusActive

Official records

From the FDA record

FDA PMA P170007

Received by the FDA
2 Mar 2017
FDA decision
29 Aug 2017
FDA review time
180 days from receipt to decision
Docket number
17M-5438
Approval order statement, verbatim
APPROVAL FOR DUROLANE. THIS DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGICAL THERAPY OR SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.

From the FDA PMA record P170007 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Across registries

2 registries list this device

  • FDA PMA P170007 decided 29 Aug 2017 Active
  • EUDAMED Active

Coverage

2 jurisdictions

United States of AmericaSwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered
  • European Union CE/MDD Active
  • United States FDA PMA Active

Specification

EUDAMED · PMA

Generic name
Acid, hyaluronic, intraarticular
FDA applicant
Bioventus, LLC
PMA number
FDA product code
MOZ
Device class
Class III
Advisory committee
Orthopedic
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

Durolane is a hyaluronic acid intraarticular injection designed for the treatment of pain associated with osteoarthritis of the knee. It is indicated for use in patients who have not responded adequately to conservative non-pharmacological therapy or simple analgesics such as acetaminophen.

This device is manufactured by Bioventus LLC and has received FDA PMA approval. It is intended for clinical application in patients meeting the specified criteria for osteoarthritis pain management.

Devices cleared under P170007

4 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P170007
UDI-DISize and differences
Durolane
MAPLESTONE DEVELOPMENTS LIMITED
N/A05065026658005 —On the market
Durolane
PAVAN TRADING LTD
N/A05060548950071 —On the market
DUROLANE 1082020
SAIMA GLOBAL FARMA S.L.
108202008437027710001 —On the market
DUROLANE 1082020
BIOVENTUS LLC
1082020 / 108202000816986020808 —On the market

Similar devices

Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).

Other devices from Bioventus LLC

See all devices from Bioventus LLC →